WO2023230486A3 - Compositions and methods for inhalable therapeutics - Google Patents

Compositions and methods for inhalable therapeutics Download PDF

Info

Publication number
WO2023230486A3
WO2023230486A3 PCT/US2023/067373 US2023067373W WO2023230486A3 WO 2023230486 A3 WO2023230486 A3 WO 2023230486A3 US 2023067373 W US2023067373 W US 2023067373W WO 2023230486 A3 WO2023230486 A3 WO 2023230486A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inhaled
compositions
concentration
therapeutic
Prior art date
Application number
PCT/US2023/067373
Other languages
French (fr)
Other versions
WO2023230486A2 (en
Inventor
Samuel K. Lai
Thomas R. Moench
Jeff T. Hutchins
Original Assignee
Inhalon Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/889,141 external-priority patent/US20230052806A1/en
Application filed by Inhalon Biopharma, Inc. filed Critical Inhalon Biopharma, Inc.
Publication of WO2023230486A2 publication Critical patent/WO2023230486A2/en
Publication of WO2023230486A3 publication Critical patent/WO2023230486A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Described herein are therapeutic inhaled antibodies and methods of delivering these therapeutic antibodies that may sustain a concentration of therapeutic inhaled antibody within the upper respiratory tract (URT) and the lower respiratory tract (LRT), as well as the blood, following even a single dose. The compositions and methods described herein may provide therapeutically-relevant levels of an inhaled antibody that is delivered by inhalation at a single dose delivered once per day or less frequently. These methods may result in a concentration in both the URT and LRT that is greater than a minimum threshold concentration having clinical relevance.
PCT/US2023/067373 2022-05-23 2023-05-23 Compositions and methods for inhalable therapeutics WO2023230486A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263345019P 2022-05-23 2022-05-23
US63/345,019 2022-05-23
US17/889,141 US20230052806A1 (en) 2021-08-16 2022-08-16 Methods and apparatuses for delivery of an agent to the lungs and nasal passages
US17/889,141 2022-08-16

Publications (2)

Publication Number Publication Date
WO2023230486A2 WO2023230486A2 (en) 2023-11-30
WO2023230486A3 true WO2023230486A3 (en) 2024-03-07

Family

ID=88920079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/067373 WO2023230486A2 (en) 2022-05-23 2023-05-23 Compositions and methods for inhalable therapeutics

Country Status (1)

Country Link
WO (1) WO2023230486A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127331A1 (en) * 2019-12-06 2022-04-28 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US20220152063A1 (en) * 2020-02-07 2022-05-19 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127331A1 (en) * 2019-12-06 2022-04-28 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US20220152063A1 (en) * 2020-02-07 2022-05-19 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STANLEY, P. ET AL.: "Chapter 8 N-Glycans", ESSENTIALS OF GLYCOBIOLOGY, 2009, pages 1, XP009553211, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/books/NBK1917> [retrieved on 20231108] *
TANG AIMIN, CHEN ZHIFENG, COX KARA S., SU HUA-POO, CALLAHAN CHERYL, FRIDMAN ARTHUR, ZHANG LAN, PATEL SANGITA B., CEJAS PEDRO J., S: "A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 10, no. 1, 1 December 2019 (2019-12-01), UK, pages 1 - 13, XP055815617, ISSN: 2041-1723, DOI: 10.1038/s41467-019-12137-1 *

Also Published As

Publication number Publication date
WO2023230486A2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
AU2022201053B2 (en) Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children
Canet et al. Postoperative pulmonary complications
Lightner et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, placebo-controlled dosing clinical trial
Zeineddine et al. Oxygen therapy in sleep-disordered breathing
US7772210B2 (en) Cystitis treatment with high dose chondroitin sulfate
Burns et al. Non-invasive ventilation versus invasive weaning in critically ill adults: a systematic review and meta-analysis
US20160271056A1 (en) Cystic fibrosis treatment comprising nitric oxide
WO2023230486A3 (en) Compositions and methods for inhalable therapeutics
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
Alfano et al. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19
Xue et al. Clinical assessment of awake endotracheal intubation using the lightwand technique alone in patients with difficult airways
JP6628449B1 (en) Composition for controlling or reducing obstructive airway disease
Sobotta et al. Case report: eculizumab and ECMO rescue therapy of severe ARDS in Goodpasture syndrome
CN102512664B (en) Nerve growth factor composition
US20210308046A1 (en) Method, Apparatus and Composition for Preventing Infection From Coronavirus, Limiting its Spread and Treatment Thereof
CN106132405B (en) The purposes of the bis- different phthalic amide of -2- mercaptoethyl of N, N-
Keibun 980: Awake ECMO and active rehabilitation strategies for venovenous ECMO as a bridge to recovery
Shiota et al. Dexmedetomidine infusion for sedation in the intensive care setting in an infant with airway compromise due to congenital mediastinal neuroblastoma.
Marcus The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease
Doherty et al. The use of low dose methylprednisolone in severe Covid-19 in-duced ARDS to facilitate oxygen weaning: Results from a case series and mini review
Lane Prediction of in-hospital mortality in exacerbations of chronic obstructive pulmonary disease requiring assisted ventilation, and patient-centred outcomes over the subsequent year
RU2429844C1 (en) Method of treating males patients suffering bronchial asthma associating early acquired androgen deficiency
Léotard et al. Impacto del tipo de mascarilla en la eficacia de la ventilación no invasiva en pacientes con enfermedad neuromuscular: un ensayo clínico aleatorizado cruzado
Jones COPD-Pathology, Diagnosis, Treatment, and Future Directions: Pathology, Diagnosis, Treatment, and Future Directions
Onotai et al. Laryngeal tumours: clinical features and management challenges as seen in two centres in Port Harcourt, Nigeria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23812729

Country of ref document: EP

Kind code of ref document: A2